DEF 14A: Ocugen Seeks Stockholder Approval for Officer Liability Limits, Share Increase, and Voting Rule Changes

Ocugen's proxy statement outlines proposals for the upcoming annual meeting, including limiting officer liability, increasing authorized shares, and adjusting voting requirements.

Summary

• Ocugen is holding its Annual Meeting of Stockholders on June 28, 2024, virtually.
• Stockholders will vote on several proposals, including the election of two Class I directors, Shankar Musunuri and Junge Zhang, for three-year terms expiring in 2027.
• Another proposal involves ratifying the appointment of Ernst & Young as the independent registered public accounting firm for 2024.
• Stockholders will also vote on a non-binding advisory basis on the compensation of the company's named executive officers (NEOs).
• A key proposal seeks approval to amend the company's charter to limit the liability of certain officers, as permitted by recent amendments to Delaware General Corporation Law (DGCL).
• Additionally, there's a proposal to amend the charter to increase the number of authorized shares of common stock.
• Another amendment aims to adjust voting requirements for certain future charter amendments in accordance with recent changes to Section 242(d) of the DGCL.
• Finally, stockholders will vote on approving an adjournment of the Annual Meeting, if necessary, to solicit additional proxies.
• As of May 23, 2024, there were 257,354,466 shares of common stock outstanding.
• Holders of Series C Preferred Stock are entitled to vote with the common stock on specific proposals.
• Shares of Series C Preferred Stock not present in person or by proxy at the Annual Meeting will be automatically redeemed.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting clinical advancements and strategic changes. However, it also acknowledges past disappointments and the need for cost-cutting measures. The overall tone suggests cautious optimism.

Positives

• The proposed officer exculpation amendment could help attract and retain qualified officers.
• Increasing authorized shares provides flexibility for future financing and strategic opportunities.
• Adjusting voting requirements could streamline certain corporate actions.
• The company has taken steps to address concerns raised in the 2023 say-on-pay vote, including resetting the peer group and changing the compensation program.
• A Lead Independent Director role was created to ensure independent oversight of management.

Negatives

• Increasing authorized shares could lead to dilution of existing stockholders' equity.
• The proposed changes to voting requirements could make it easier for the company to approve certain actions without broad stockholder support.
• The say-on-pay vote at the 2023 annual meeting received only 57.28% support, indicating some stockholder dissatisfaction with executive compensation.

Risks

• Future issuance of additional shares of common stock or securities convertible into common stock may occur at times or under circumstances that could result in a dilutive effect on the earnings per share, book value per share, voting power and percentage interest of the present holders of our common stock.
• An increase in the number of authorized shares of common stock may also, under certain circumstances, be construed as having an anti-takeover effect.
• The use of super-voting preferred stock, such as the Series C Preferred Stock, to approve an amendment to a company's certificate of incorporation has not been validated by a Delaware court to date and has been neither specifically prohibited by, nor provided for, in applicable statutes.

Future Outlook

The company aims to bring game-changing therapies and vaccines to market and provide access to patients globally.

Management Comments

• 2023 was a year of much change at Ocugen.
• These changes required us to take a close look at the business and determine the fundamental programs, processes and people needed to ensure success in 2024 and beyond.
• In the midst of resetting the organization, we didn't slow down.
• The Ocugen team delivered on important milestones, established new partnerships, and renewed our commitment to help patients for whom no hope exists.
• Every day, we are driven by our mission to bring game-changing therapies and vaccines to market and working even harder to provide access to patients globally.
• Thank you for believing in Ocugen, but more importantly sharing our dedication to the patients we serve.

Industry Context

The proposed officer exculpation amendment aligns with a trend among public companies in states that allow it, aiming to attract and retain qualified individuals. The amendments to Section 242 of the DGCL provide a benefit to stockholders as they allow corporations to more easily approve a reverse stock split and therefore maintain their listing.

Comparison to Industry Standards

• The company is updating its peer group to better reflect its pre-commercial status and market capitalization, aligning with industry best practices for executive compensation benchmarking.
• The company is seeking to obtain the same benefits of the new Section 242 modified vote thresholds as its peers.

Management Changes

Corporate Governance

Related Party Transactions

• In February 2021, we entered into a sponsored research agreement (as amended, the UoC Agreement) with the Regents of the University of Colorado, for and on behalf of the University of Colorado, Denver (UoC Denver).
• In December 2021, we entered into an agreement with Advaite, Inc. (Advaite) to purchase 2,000 COVID-19 SalivaDirect Collection Test Kits (the test kit) for use in our Phase 2/3 immuno-bridging and broadening safety trial for COVAXIN.
• In March 2022, we entered into a services agreement with Advaite to engage them to develop and validate bioanalytical methods for SARS-CoV-2 Spike S1 ELISA, in support of our trials and ongoing research.

Stakeholder Impact

• Approval of the proposals could impact shareholders through potential dilution and changes in voting power.
• Employees may be affected by changes in executive compensation and the company's ability to attract and retain talent.
• Customers and partners could benefit from the company's increased financial flexibility and strategic opportunities.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on June 28, 2024.
• The company will file the Certificate of Amendment with the Secretary of State of the State of Delaware if the proposals are approved.
• The company intends to continue engaging with its stockholders and reviewing its compensation and governance practices in the future.

Key Dates

Keywords

proxy statement, annual meeting, officer liability, authorized shares, voting requirements, executive compensation, directors, corporate governance, Ocugen